Back to Search
Start Over
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia
- Source :
- Blood, 111(5), 2581-2588. American Society of Hematology, Blood, 111(5), 2581-2588. AMER SOC HEMATOLOGY, Blood, 111, 5, pp. 2581-2588, Deenik, W, van der Holt, B, Verhoef, GE, Smit, W M, Kersten, M J, Kluin-Nelemans, H C, Verdonck, L F, Ferrant, A, Schattenberg, A V, Janssen, J J W M, Sonneveld, P, van Marwijk, K M, Wittebol, S, Willemze, R, Wijermans, P W, Westveer, PH, Beverloo, HB, van der Valk, P, Lowenberg, B, Ossenkoppele, G J & Cornelissen, J J 2008, ' Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia ', Blood, vol. 111, no. 5, pp. 2581-2588 . https://doi.org/10.1182/blood-2007-08-107482, Blood, 111, 2581-2588
- Publication Year :
- 2008
-
Abstract
- Contains fulltext : 70504schattenberg.pdf (Publisher’s version ) (Closed access) The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase chronic myeloid leukemia (CML). Patients received 2 cycles of intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1-7) in conjunction with imatinib (200 mg, 400 mg, 600 mg, or 800 mg), according to predefined, successive dose levels. All dose levels proved feasible. Seven dose-limiting toxicities (DLTs) were observed in 302 cycles of chemotherapy, which were caused by streptococcal bacteremia in 5 cases. Intermediate-dose cytarabine (1000 mg/m(2)) prolonged time to neutrophil recovery and platelet recovery compared with a standard dose (200 mg/m(2)). High-dose imatinib (600 mg or 800 mg) extended the time to platelet recovery compared with a standard dose (400 mg). More infectious complications common toxicity criteria (CTC) grade 3 or 4 were observed after intermediate-dose cytarabine compared with a standard-dose of cytarabine. Early response data after combination therapy included a complete cytogenetic response in 48% and a major molecular response in 30% of patients, which increased to 46% major molecular responses at 1 year, including 13% complete molecular responses. We conclude that combination therapy of escalating dosages of imatinib and cytarabine is feasible. This study was registered at www.kankerbestrijding.nl as no. CKTO-2001-03. 8 p.
- Subjects :
- Male
CHROMOSOME
medicine.medical_treatment
FEATURES
Pharmacology
Biochemistry
Gastroenterology
Piperazines
RECOMMENDATIONS
BRAIN-ABSCESS
Antineoplastic Combined Chemotherapy Protocols
Medicine
Molecular diagnosis, prognosis and monitoring [UMCN 1.2]
Hematologic Tests
CHRONIC MYELOGENOUS LEUKEMIA
Cytarabine
Myeloid leukemia
Hematology
Middle Aged
Benzamides
Cytogenetic Analysis
Injections, Intravenous
Imatinib Mesylate
Female
TYROSINE KINASE INHIBITOR
Physical Organic Chemistry
medicine.drug
Adult
INTERFERON
medicine.medical_specialty
Combination therapy
medicine.drug_class
Immunology
MESYLATE
Antineoplastic Agents
Antimetabolite
Communicable Diseases
Internal medicine
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NEUTROPENIC PATIENTS
Humans
Mortality
Aged
Chemotherapy
Dose-Response Relationship, Drug
business.industry
CHRONIC-PHASE
Imatinib
Cell Biology
medicine.disease
Imatinib mesylate
Pyrimidines
Feasibility Studies
business
Chronic myelogenous leukemia
Subjects
Details
- ISSN :
- 00064971
- Volume :
- 111
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi.dedup.....1f131f5681d74cee672cbe2409de65f3